

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CT Vision S.L. (International) Holdings Limited**

**中天順聯(國際)控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 994)**

## **ANNOUNCEMENT PURSUANT TO RULES 13.51(2)(U) AND 13.51B(2) OF THE LISTING RULES**

This announcement is made by CT Vision S.L. (International) Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.51(2) (u) and 13.51B(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board (the “**Board**”) of directors of the Company (the “**Directors**”) noticed that the Securities and Futures Commission (the “**SFC**”) has published news (the “**News**”) on 19 September 2025 in relation to, among other things, the legal proceedings (the “**Legal Proceedings**”) commenced by the SFC in the Court of First Instance to seek disqualification orders against four former directors of Century Energy International Holdings Limited (formerly known as China Oil Gangran Energy Group Holdings Limited) (“**COGE**”) (Stock Code: 8132), including Dr. Ho Chun Kit Gregory (“**Dr. Ho**”), under section 214 of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong). Dr. Ho is a non-executive Director. For details of the Legal Proceedings, please refer to the News published on the website of the SFC.

The Board further noticed that (i) the News and Legal Proceedings only relate to COGE and former directors of COGE, but not the Group, the Directors (other than Dr. Ho) and senior management of the Group; and (ii) the Court of First Instance has not made any binding decision or conclusion in the Legal Proceedings against Dr. Ho as at the date of this announcement.

The Board has carefully reviewed the News and make the necessary enquires with Dr. Ho. Having considered the following reasons, Dr. Ho considers, and all other Directors concur, that Dr. Ho remains suitable to act as non-executive Director:

1. the Court of First Instance had not made any binding decision or conclusion that Dr. Ho is unsuitable to act as a director of listed companies in Hong Kong; and
2. the incidents and the allegations of SFC as disclosed in the News do not involve any dishonesty, fraud or integrity issues on the part of Dr. Ho.

As disclosed in the announcement of the Company dated 25 April 2023, Dr. Ho has been redesignated from executive Director to non-executive Director with effect from 25 April 2023. Since the redesignation, Dr. Ho has not taken part in the daily operation of the Group. In the light of the foregoing and the Legal Proceedings are not related to other Directors, senior management and business of the Group, the Company confirms that the Legal Proceedings will not adversely affect the business and operations of the Group.

Save as disclosed in the News and this announcement, Dr. Ho has confirmed to the Company that there is no other information relating to him that is required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) and Rule 13.51B(2) of the Listing Rules and he is not aware of any other matters that need to be brought to the attention of the shareholders of the Company.

The Company will monitor the matters disclosed in this announcement and make further announcements in accordance with the applicable requirements of the Listing Rules as and when appropriate.

By order of the Board  
**CT Vision S.L. (International) Holdings Limited**  
**Sun Dexin**  
*Executive Director*

Hong Kong, 21 September 2025

*As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Wu Rui, Mr. Guo Jianfeng, Mr. Ding Ji and Mr. Sun Dexin, one non-executive Director, namely Dr. Ho Chun Kit Gregory, and three independent non-executive Directors, namely Dr. Tang Dajie, Dr. Lin Tat Pang and Ms. Liu Zhen.*